SBIR-STTR Award

Development of a Rapid in Vitro Screening Assay for Detection of Cancer Biomarke
Award last edited on: 9/9/2014

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$200,000
Award Phase
1
Solicitation Topic Code
NCI
Principal Investigator
Franklin O Kroh

Company Information

NanoScale Corporation (AKA: Nantek Inc~Nanoscale Materials Inc)

1310 Research Park Drive
Manhattan, KS 66502
   (785) 537-0179
   custserv@nanoactive.com
   www.nanoscalecorp.com
Location: Single
Congr. District: 01
County: Riley

Phase I

Contract Number: 261201100069C-0-0-1
Start Date: 9/15/2011    Completed: 6/14/2012
Phase I year
2011
Phase I Amount
$200,000
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in urine and blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in urine and blood via simple fluorescence measurements. The severing from the nanoparticle stops the efficient fluorescence quenching of the organic luminophore by the nanoparticle, thus allowing the detection of the protease activity. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/ invasion. The focus will be on pancreatic cancer, and the studies will be done on urine and blood from 30 patients and 12 healthy individuals. Measuring twelve proteases in total that are linked to pancreatic cancer progression will allow us to obtain statistically significant measurements within 1 hour.

NIH Spending Category:
Bioengineering; Cancer; Clinical Research; Nanotechnology; Pancreatic Cancer; Prevention; Rare Diseases

Project Terms:
angiogenesis; base; Biological Assay; Biological Markers; Blood; Buffers; Cancer Detection; Cancer Patient; Cathepsin E; Cathepsin L; Cathepsins; Cathepsins B; Cell Survival; Clinical Protocols; Clinical Research; collagenase 3; Consensus; Consensus Sequence; cyanine dye; Data Correlations; Detection; Development; Enzymes; Fluorescence; Gelatinase A; Gelatinase B; Goals; Histology; Hour; Human; In Vitro; Individual; Institutional Review Boards; Interstitial Collagenase; Kansas; Link; Malignant neoplasm of pancreas; Malignant Neoplasms; Matrilysin; Matrix Metalloproteinases; Measurement; Measures; Medical center; nanoparticle; Patients; Peptide Hydrolases; Preparation; Reaction Time; Screening procedure; sensor; Serum; Solutions; Stromelysin 1; Testing; Tissues; tumor progression; Universities; Urine; Urokinase; Validation

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----